Keywords: AstraZeneca, Rigel Pharma, Fostamatinib, Rheumatoid arthritis, Ph IIb

AstraZeneca presents mixed data on fostamatinib in RA

Article | 13 December 2012

Shares of Anglo-Swedish drug major AstraZeneca (LSE: AZN) fell 2.1% to $47.88 in premarket US trading yesterday, after the company announced mixed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Rigel Pharmaceuticals

AstraZeneca

Go to company listing

Related Drugs

fostamatinib

Go to drug listing